Choice of starting dose for molecular targeted agents (MTA) evaluated in phase I cancer clinical trials (P1T)

2008 ◽  
Vol 26 (15_suppl) ◽  
pp. 3586-3586
Author(s):  
L. Vidal-Boixader ◽  
C. Le Tourneau ◽  
L. L. Siu
Keyword(s):  
Clinical Trials ◽  
Phase I ◽  
Cancer Clinical Trials ◽  
Targeted Agents ◽  
Starting Dose ◽  
Molecular Targeted Agents

scholarly journals Choice of Starting Dose for Biopharmaceuticals in First‐in‐Human Phase I Cancer Clinical Trials

2015 ◽  
Vol 20 (6) ◽  
pp. 653-659 ◽  
Author(s):  
Aaron R. Hansen ◽  
Natalie Cook ◽  
M. Stacey Ricci ◽  
Albiruni Razak ◽  
Christophe Le Tourneau ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Phase I ◽  
Cancer Clinical Trials ◽  
Starting Dose

Choice of starting dose for biopharmaceuticals in first-in-human phase I cancer clinical trials.

2014 ◽  
Vol 32 (15_suppl) ◽  
pp. 2596-2596
Author(s):  
Aaron Richard Hansen ◽  
Natalie Cook ◽  
M Stacey Ricci ◽  
Albiruni R. A. Razak ◽  
Christophe Le Tourneau ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Phase I ◽  
Cancer Clinical Trials ◽  
Starting Dose

384 POSTER Effect of selection of QTc formula on eligibility of patients for phase I cancer clinical trials

2008 ◽  
Vol 6 (12) ◽  
pp. 120
Author(s):  
M. Benjamin ◽  
D. Casa ◽  
W. Tembe ◽  
B. Piper ◽  
S. Anthony ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Phase I ◽  
Cancer Clinical Trials ◽  
Selection Of

29 A new bayesian design for phase I cancer clinical trials

1997 ◽  
Vol 18 (3) ◽  
pp. S58
Author(s):  
Alicia Y. Toledano ◽  
Rosemarie Mick
Keyword(s):  
Clinical Trials ◽  
Phase I ◽  
Cancer Clinical Trials ◽  
Bayesian Design
Sign in / Sign up

Export Citation Format

Share Document